Targeting HER 1 and 2 in breast cancer with lapatinib

  • Gerald M. Higa | ghiga@hsc.wvu.edu Associate Professor Mary Babb Randolph Cancer Center, School of Pharmacy, West Virginia University, Morgantown, United States.

Abstract

Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and potentially curable, disease. Until recently, development of resistance to trastuzumab left patients with no therapeutic option other than specifically targeted HER2. This paper provides an in-depth review of lapatinib, a dual HER kinase inhibitor, as well as some insight into three HER family members, in breast cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Reviews
Keywords:
EGFR - HER1 - HER2 - HER3 - Lapatinib
Statistics
  • Abstract views: 903

  • FULL TEXT: 140
How to Cite
Higa, G. M. (2011). Targeting HER 1 and 2 in breast cancer with lapatinib. Oncology Reviews, 2(1), 21-28. https://doi.org/10.4081/oncol.2008.105